Argenx Says Vyvgart Sales Rose 54% in Third Quarter
Argenx said global sales of its Vyvgart autoimmune drug rose 54% in the third quarter.
Belgian-Dutch pharmaceutical firm argenx EURONEXT:ARGX said on Thursday that global sales of its leading autoimmune drug Vyvgart rose 54% in the third quarter, as it reached more patients.Sales of Vyvgart, a prescription drug used to treat adults with generalized myasthenia gravis, an autoimmune di…